Articles published by Gilead Sciences, Inc.

< Previous 1 2 3 4 5 6 7 8 9 Next >
Yescarta® CAR T-cell Therapy Demonstrates Consistent Survival Outcomes and Safety in Real-World Setting Regardless of Race and Ethnicity
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences Appoints Stacey Ma, PhD as Executive Vice President, Pharmaceutical Development and Manufacturing
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Reaches Number One Spot as Top Overall Philanthropic Funder of HIV-Related Programs, According to Funders Concerned About AIDS Report
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead and Kite Oncology to Highlight Advances Supporting New Innovations in Cancer Care at the ASCO Annual Meeting
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences Announces First Quarter 2022 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Veklury® (Remdesivir) is First and Only Approved Treatment for Pediatric Patients Under 12 Years of Age with COVID-19
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Several New Studies Presented at ECCMIC 2022 Confirm Veklury® (Remdesivir) Activity in Treating COVID-19
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Kite Receives U.S. FDA Approval of New State-of-the-Art CAR T-Cell Therapy Manufacturing Facility in Maryland
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences to Release First Quarter 2022 Financial Results on Thursday, April 28, 2022
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Yescarta® Receives U.S. FDA Approval as First CAR T-cell Therapy for Initial Treatment of Relapsed or Refractory Large B-cell Lymphoma (LBCL)
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences Announces $24 Million in Grants to Help End the HIV Epidemic for Everyone, Everywhere
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
New Clinical Data Support the Sustained Efficacy of Long-acting Lenacapavir, Gilead’s Investigational HIV-1 Capsid Inhibitor
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Phase 2/3 Interim Data Evaluating the Safety, Tolerability and Clinical Outcomes of Veklury® (Remdesivir) in Pediatric Patients With COVID-19 Presented at CROI 2022
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression at Five Years, in Treatment-Naïve Adults
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Veklury® (Remdesivir) Retains Antiviral Activity Against Omicron, Delta and Other Emergent SARS-CoV-2 Variants in Multiple In Vitro Studies
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead to Present Latest Antiviral Research and Development Data at CROI 2022 Addressing Urgent Global Needs
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences Announces 2.8 Percent Increase in First Quarter 2022 Dividend
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences Announces Fourth Quarter and Full Year 2021 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
U.S. FDA Approves New Label Update for CAR T-Cell Therapy Yescarta® Showing Prophylactic Steriod Use Improves Management of Cytokine Release Syndrome
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
FDA Approves Veklury® (Remdesivir) for the Treatment of Non-Hospitalized Patients at High Risk for COVID-19 Disease Progression
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences to Release Fourth Quarter & Full Year 2021 Financial Results on Tuesday, February 1, 2022
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy® in Combination With KEYTRUDA® in First-Line Metastatic Non-Small Cell Lung Cancer
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Announces New England Journal of Medicine Publication of Data Demonstrating Veklury® (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients With COVID-19
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Announces Clinical Hold on Studies Evaluating Injectable Lenacapavir for HIV Treatment and Prevention Due to Vial Quality Concerns
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences to Present at Upcoming Investor Conference
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.